Patents by Inventor Weizao Chen
Weizao Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230357410Abstract: The present invention provides recombinant bispecific antibodies designed to bind to a surface antigen on target cells and to an activating component on immune cells such as T cells. The bispecific antibodies comprise two polypeptide chains that contain Fv and Fab as antigenĀ¬ binding fragments and a modified Fc region to facilitate heterodimer formation. In one embodiment, the bispecific antibodies further comprise protease cleavage sites and/or motifs that would cause steric occlusion of the antigen binding sites so that the antibodies would be activated only in a specific environment, e.g. in the vicinity of a tumor. In another embodiment, the bispecific antibodies comprise modified sequences that confer reduced binding affinity to CDS and/or cross-reactive binding to CDS on cells from different species.Type: ApplicationFiled: December 20, 2019Publication date: November 9, 2023Applicant: Zhejiang Shimai Pharmaceutical Co.,Ltd.Inventors: Weizao Chen, Yanping Wang, Zuoxiang Xiao
-
Patent number: 11339218Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to LAG3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human LAG3. In certain embodiments, the antibodies bind both human and monkey LAG3 but do not bind mouse LAG3. The invention provides anti-LAG3 antibodies that can inhibit the binding of LAG3 to MHC Class II molecules and that can stimulate antigen-specific T cell responses. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. This disclosure also provides methods for stimulating an immune response, as well as methods for treating cancer using an anti-LAG3 antibody of the invention.Type: GrantFiled: May 9, 2018Date of Patent: May 24, 2022Assignee: Zhejiang Shimai Pharmaceutical Co., Ltd.Inventors: Weizao Chen, Tao Fu, Zuoxiang Xiao
-
Publication number: 20220127367Abstract: Human monoclonal antibodies that specifically bind Fms-like tyrosine kinase 3 (FLT3) are described. Chimeric antigen receptors (CARs) and other antibody conjugates that include the FLT3-specific monoclonal antibodies are also described. Methods for the diagnosis and treatment of FLT3-associated cancer, such as acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML), are further described.Type: ApplicationFiled: January 6, 2022Publication date: April 28, 2022Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventors: Dimiter S. Dimitrov, Weizao Chen, Terry J. Fry, Christopher Chien
-
Patent number: 11236171Abstract: Human monoclonal antibodies that specifically bind Fms-like tyrosine kinase 3 (FLT3) are described. Chimeric antigen receptors (CARs) and other antibody conjugates that include the FLT3-specific monoclonal antibodies are also described. Methods for the diagnosis and treatment of FLT3-associated cancer, such as acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML), are further described.Type: GrantFiled: December 21, 2017Date of Patent: February 1, 2022Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Dimiter S. Dimitrov, Weizao Chen, Terry J. Fry, Christopher Chien, Haiying Qin
-
Publication number: 20210388118Abstract: The present invention provides recombinant bispecific antibodies designed to bind to a surface antigen on target cells and to an activating component on immune cells such as T cells. The bispecific antibodies comprise two polypeptide chains that contain Fv and Fab as antigen-binding fragments and a modified Fc region to facilitate heterodimer formation In one embodiment, the bispecific antibodies further comprise protease cleavage sites and/or motifs that would cause steric occlusion of the antigen binding sites so that the antibodies would be activated only in a specific environment, e.g. in the vicinity of a tumor. In another embodiment, the bispecific antibodies comprise modified sequences that confer reduced binding affinity to CDS and/or cross-reactive binding to CDS on cells from different species.Type: ApplicationFiled: August 27, 2021Publication date: December 16, 2021Applicant: Zhejiang Shimai Pharmaceutical Co. Ltd.Inventors: Weizao Chen, Yanping Wang, Zuoxiang Xiao
-
Publication number: 20210115135Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to LAG3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human LAG3. In certain embodiments, the antibodies bind both human and monkey LAG3 but do not bind mouse LAG3. The invention provides anti-LAG3 antibodies that can inhibit the binding of LAG3 to MHC Class II molecules and that can stimulate antigen-specific T cell responses. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. This disclosure also provides methods for stimulating an immune response, as well as methods for treating cancer using an anti-LAG3 antibody of the invention.Type: ApplicationFiled: May 9, 2018Publication date: April 22, 2021Inventors: Weizao CHEN, Tao Fu, Zuoxiang XIAO
-
Patent number: 10647754Abstract: The invention provides a polypeptide comprising a single domain CD4, as well as a fusion protein comprising the single domain CD4 and one or more fusion partners. A nucleic acid encoding the polypeptide or fusion protein, as well as compositions or cells comprising the polypeptide, fusion protein, or nucleic acid also are provided.Type: GrantFiled: October 16, 2017Date of Patent: May 12, 2020Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Dimiter S. Dimitrov, Weizao Chen, Prabakaran Ponraj
-
Publication number: 20190367611Abstract: The present invention relates to monomeric Fc (mFc) polypeptides and methods of making and using such polypeptides. The polypeptides comprise IgG1 Fc domain with mutation of one or two residues (T366 and Y407) in the CH3 hydrophobic interface. The present invention also discusses methods of making bispecific antibodies comprising mFc and variants thereof.Type: ApplicationFiled: February 1, 2018Publication date: December 5, 2019Inventors: Weizao CHEN, Zuoxiang XIAO, Tao FU
-
Publication number: 20190352408Abstract: Human monoclonal antibodies that specifically bind Fms-like tyrosine kinase 3 (FLT3) are described. Chimeric antigen receptors (CARs) and other antibody conjugates that include the FLT3-specific monoclonal antibodies are also described. Methods for the diagnosis and treatment of FLT3-associated cancer, such as acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML), are further described.Type: ApplicationFiled: December 21, 2017Publication date: November 21, 2019Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventors: Dimiter S. Dimitrov, Weizao Chen, Terry J. Fry, Christopher Chien
-
Patent number: 10472412Abstract: The invention provides a construct comprising two or more fusion proteins of Formulas (I)-(IV): A-(optional linker)-C-(optional linker)-B (Formula I), B-(optional linker)-D-(optional linker)-E-(optional linker)-B (Formula II), A-(optional linker)-C (Formula III), and B-(optional linker)-D-(optional linker)-E (Formula IV), wherein A denotes an antibody or antibody fragment, B denotes a single domain CD4, C denotes an immunoglobulin light chain constant region D denotes an immunoglobulin heavy chain constant region, and E denotes an Fc region or a portion thereof that is optionally defucosylated.Type: GrantFiled: December 16, 2015Date of Patent: November 12, 2019Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Fudan UniversityInventors: Dimiter S. Dimitrov, Weizao Chen, Tianlei Ying
-
Patent number: 10287340Abstract: The invention provides single domain antibodies and derivatives thereof that bind antigens of interest, which are stable, soluble, and do not tend to aggregate. The invention also provides methods for constructing a dAb library and methods for screening dAb libraries to identify the dAb of the invention. The invention also provide methods of treating or preventing conditions by antigen neutralization by administering the dAbs of the invention.Type: GrantFiled: September 28, 2015Date of Patent: May 14, 2019Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Dimiter S. Dimitrov, Weizao Chen
-
Publication number: 20180118815Abstract: The invention provides a construct comprising two or more fusion proteins of Formulas (I)-(IV): A-(optional linker)-C-(optional linker)-B (Formula I), B-(optional linker)-D-(optional linker)-E-(optional linker)-B (Formula II), A-(optional linker)-C (Formula III), and B-(optional linker)-D-(optional linker)-E (Formula IV), wherein A denotes an antibody or antibody fragment, B denotes a single domain CD4, C denotes an immunoglobulin light chain constant region D denotes an immunoglobulin heavy chain constant region, and E denotes an Fc region or a portion thereof that is optionally defucosylated.Type: ApplicationFiled: December 16, 2015Publication date: May 3, 2018Applicants: The United States of America, as Represented by the Secretary, Dept. of Health and Human Resources, Fudan UniversityInventors: Dimiter S. Dimitrov, Weizao Chen, Tianlei Ying
-
Publication number: 20180086812Abstract: The invention provides a polypeptide comprising a single domain CD4, as well as a fusion protein comprising the single domain CD4 and one or more fusion partners. A nucleic acid encoding the polypeptide or fusion protein, as well as compositions or cells comprising the polypeptide, fusion protein, or nucleic acid also are provided.Type: ApplicationFiled: October 16, 2017Publication date: March 29, 2018Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Dimiter S. Dimitrov, Weizao Chen, Prabakaran Ponraj
-
Patent number: 9657096Abstract: Antibodies and antibody fragments that bind to insulin-like growth factor (IGF) 1 receptor (IGF-1R) or IGF-2, as well as methods of using the antibodies for inhibiting the IGF-mediated signaling pathway, inhibiting IGF-1R signaling, and treating cancer, are described. A method of detecting the presence of IGF-1R or IGF-2 in a sample using the disclosed antibodies and antibody fragments is also described.Type: GrantFiled: May 13, 2015Date of Patent: May 23, 2017Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Dimiter S. Dimitrov, Weizao Chen
-
Publication number: 20160207985Abstract: The invention provides single domain antibodies and derivatives thereof that bind antigens of interest, which are stable, soluble, and do not tend to aggregate. The invention also provides methods for constructing a dAb library and methods for screening dAb libraries to identify the dAb of the invention. The invention also provide methods of treating or preventing conditions by antigen neutralization by administering the dAbs of the invention.Type: ApplicationFiled: September 28, 2015Publication date: July 21, 2016Inventors: Dimiter S. Dimitrov, Weizao Chen
-
Publication number: 20160039904Abstract: The invention provides a polypeptide comprising a single domain CD4, as well a fusion protein comprising the single domain CD4 and one or more fusion partners. A nucleic acid encoding the polypeptide or fusion protein, as well as compositions or cells comprising the polypeptide, fusion protein, or nucleic acid also are provided.Type: ApplicationFiled: March 12, 2014Publication date: February 11, 2016Inventors: Dimiter S. Dimitrov, Weizao Chen, Prabakaran Ponraj
-
Patent number: 9181327Abstract: The invention provides single domain antibodies and derivatives thereof that bind antigens of interest, which are stable, soluble, and do not tend to aggregate. The invention also provides methods for constructing a dAb library and methods for screening dAb libraries to identify the dAb of the invention. The invention also provide methods of treating or preventing conditions by antigen neutralization by administering the dAbs of the invention.Type: GrantFiled: January 7, 2009Date of Patent: November 10, 2015Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Dimiter S. Dimitrov, Weizao Chen
-
Patent number: 9127056Abstract: Monoclonal antibodies (mAbs), antigen binding fragments and engineered antibody domains (eAds) that specifically bind IGF-II are disclosed herein. In some embodiments, these mAbs and eAds are included in a bispecific mAb. In some embodiments, the bispecific antibody specifically binds two different epitopes of IGF-II. Methods of using these mAbs, antigen binding fragments, and eAds, bispecific antibodies, and nucleic acids encoding these mAbs, antigen binding fragments, and eAds, bispecific antibodies are also disclosed.Type: GrantFiled: October 16, 2012Date of Patent: September 8, 2015Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Dimiter S. Dimitrov, Weizao Chen, Yang Feng
-
Publication number: 20150246967Abstract: Antibodies and antibody fragments that bind to insulin-like growth factor (IGF) 1 receptor (IGF-1R) or IGF-2, as well as methods of using the antibodies for inhibiting the IGF-mediated signaling pathway, inhibiting IGF-1R signaling, and treating cancer, are described. A method of detecting the presence of IGF-1R or IGF-2 in a sample using the disclosed antibodies and antibody fragments is also described.Type: ApplicationFiled: May 13, 2015Publication date: September 3, 2015Applicant: The United States of America, as represented by the Secretary, Dept. of Health & Human ServicesInventors: Dimiter S. Dimitrov, Weizao Chen
-
Patent number: 9056907Abstract: The invention provides antibodies or antibody fragments that bind to insulin-like growth factor (IGF) 1 receptor (IGF-1R) or IGF-2, as well as method of using the antibodies for inhibiting the IGF-mediated signaling pathway, inhibiting IGF-1R signaling, and treating cancer. The invention also provides a method of detecting the presence of IGF-1R or IGF-2 in a sample using the inventive antibodies and antibody fragments.Type: GrantFiled: October 7, 2010Date of Patent: June 16, 2015Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Dimiter S. Dimitrov, Weizao Chen